Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,703 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies.
Rixe O, Puzanov I, LoRusso PM, Cohen RB, Morris JC, Olowokure OO, Yin JY, Doroumian S, Shen L, Olszanski AJ. Rixe O, et al. Among authors: morris jc. Anticancer Drugs. 2015 Aug;26(7):785-92. doi: 10.1097/CAD.0000000000000250. Anticancer Drugs. 2015. PMID: 26020806 Free PMC article. Clinical Trial.
Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study.
Sarantopoulos J, Mita AC, He A, Wade JL, Hsueh CT, Morris JC, Lockhart AC, Quinn DI, Hwang J, Mier J, Zhang W, Wack C, Yin J, Clot PF, Rixe O. Sarantopoulos J, et al. Among authors: morris jc. Cancer Chemother Pharmacol. 2017 Feb;79(2):339-351. doi: 10.1007/s00280-016-3210-8. Epub 2017 Jan 5. Cancer Chemother Pharmacol. 2017. PMID: 28058445 Free PMC article. Clinical Trial.
A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies.
Wise-Draper TM, Moorthy G, Salkeni MA, Karim NA, Thomas HE, Mercer CA, Beg MS, O'Gara S, Olowokure O, Fathallah H, Kozma SC, Thomas G, Rixe O, Desai P, Morris JC. Wise-Draper TM, et al. Among authors: morris jc. Target Oncol. 2017 Jun;12(3):323-332. doi: 10.1007/s11523-017-0482-9. Target Oncol. 2017. PMID: 28357727 Free PMC article. Clinical Trial.
A Phase I Trial to Determine the Safety and Tolerability of Autophagy Inhibition Using Chloroquine or Hydroxychloroquine in Combination With Carboplatin and Gemcitabine in Patients With Advanced Solid Tumors.
Karim NA, Ullah A, Ahmad I, Bahassi E, Olowokure O, Khaled A, Davis H, Morris JC. Karim NA, et al. Among authors: morris jc. Front Oncol. 2022 Apr 26;12:811411. doi: 10.3389/fonc.2022.811411. eCollection 2022. Front Oncol. 2022. PMID: 35574311 Free PMC article.
Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.
Sarantopoulos J, Mita AC, Wade JL, Morris JC, Rixe O, Mita MM, Dedieu JF, Wack C, Kassalow L, Lockhart AC. Sarantopoulos J, et al. Among authors: morris jc. Cancer Chemother Pharmacol. 2014 Dec;74(6):1113-24. doi: 10.1007/s00280-014-2572-z. Epub 2014 Oct 12. Cancer Chemother Pharmacol. 2014. PMID: 25307552 Clinical Trial.
Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma.
Sharma K, Janik JE, O'Mahony D, Stewart D, Pittaluga S, Stetler-Stevenson M, Jaffe ES, Raffeld M, Fleisher TA, Lee CC, Steinberg SM, Waldmann TA, Morris JC. Sharma K, et al. Among authors: morris jc. Clin Cancer Res. 2017 Jan 1;23(1):35-42. doi: 10.1158/1078-0432.CCR-16-1022. Epub 2016 Aug 2. Clin Cancer Res. 2017. PMID: 27486175 Free PMC article. Clinical Trial.
1,703 results